To study SCLC heterogeneity during cancer malignant progression and metastasis, we first performed immunohistochemistry (IHC) staining in RP tumors using NE marker NCAM and mesenchymal marker CD44. This evidence concerns the gene CD44 and small cell lung carcinoma.